Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment

Authors
Category Primary study
JournalNeurology and Therapy
Year 2022
This article has no abstract
Epistemonikos ID: 85a8cccb325d4a2368f50dd2189c203e6751f581
First added on: Feb 14, 2025